Role of EZH2 Inhibitor Combined with Gefitinib in EGFR-TKIs Resistant Lung Cancer Cells

Conclusion The combination of EZH2 inhibitor GSK343 and gefitinib sensitize PC9/AB2 cell to gefitinib response. This study also suggests that synergistic therapy plays a role in the reversal of EGFR-tyrosine kinase inhibitor (EGFR-TKIs) resistance in lung cancer. 
 DOI: 10.3779/j.issn.1009-3419.2019.05.01
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research